U.S. Judge On Wednesday Set Aside A Jury Verdict That Amgen Inc Patents On Its Cholesterol Medication Repatha Were Valid, Handing A Victory To Regeneron Pharmaceuticals Inc And Sanofi Sa, Which Make A Rival Drug.The Ruling From U.S. District Judge Richard Andrews In Wilmington, Delaware Was The Latest Reversal Of Fortune In A Long-Running Lawsuit In Which Amgen Is Seeking To Stop Sanofi And Regeneron From Selling Their Drug Praluent. The Drug Competes With Repatha And Is Intended To Lower So-Called Bad Ldl Cholesterol By Blocking A Protein Known As Pcsk9
